Breast Disease pp 387-392 | Cite as

Surveillance of Patients Following Primary Therapy

  • Varol Çelik
  • Tümay Aydoğan
  • Mehmet Halit Yilmaz
  • Nejdet Fatih Yaşar
  • Mahmut Müslümanoğlu


Regular and appropriate follow-up of patients after treatment for breast cancer is an important aspect of comprehensive care. Breast cancer survival has increased due to improvements of treatment, leading to a much higher long-term survival of women diagnosed with breast cancer. The primary purpose of follow-up is often regarded as the early detection of recurrence as well as the detection of second primary tumors along with long-term sequelae of breast cancer treatment.


Breast cancer Surveillance of patients Follow-up Follow-up program Survival Recurrence 


  1. 1.
    DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.CrossRefGoogle Scholar
  2. 2.
    Rojas MP, Telaro E, Russo A, Fossati R, Confalonieri C, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;1:CD001768.Google Scholar
  3. 3.
    Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract. 1999;49:705–10.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, et al. Routine follow up of breast cancer in primary care: randomized trial. BMJ. 1996;313:665–9.CrossRefGoogle Scholar
  5. 5.
    Hollowell K, Olmsted CL, Richardson AS, Pittman HK, Bellin L, et al. American Society of Clinical Oncology-recommended surveillance and physician specialty among long term breast cancer survivors. Cancer. 2010;116:2090–8.PubMedGoogle Scholar
  6. 6.
    Chalasani P, Downey L, Stopeck AT. Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med. 2010;123:489–95.CrossRefGoogle Scholar
  7. 7.
    Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.CrossRefGoogle Scholar
  8. 8.
    Voogd AC, van Oost FJ, Rutgers EJ, Elkhuizen PH, van Geel AN, Scheijmans LJ, et al. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer. 2005;41:2637–44.CrossRefGoogle Scholar
  9. 9.
    Haffty BG, Carter D, Flynn SD, Fischer DB, Brash DE, Simons J, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys. 1993;27:575–83.CrossRefGoogle Scholar
  10. 10.
    van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer. 1999;35:32–8.CrossRefGoogle Scholar
  11. 11.
    Francis M, Cakir B, Ung O, Gebski V, Boyages J. Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer. Br J Surg. 1999;86:1556–62.CrossRefGoogle Scholar
  12. 12.
    Buist DS, Abraham LA, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, Breast Cancer Surveillance Consortium, et al. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Treat. 2010;124:863–73.CrossRefGoogle Scholar
  13. 13.
    Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–14.CrossRefGoogle Scholar
  14. 14.
    Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, American Society of Clinical Oncology, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24:5091–7.CrossRefGoogle Scholar
  15. 15.
    de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol. 2004;22:4010–8.CrossRefGoogle Scholar
  16. 16.
    Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009;114:403–128. Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med. 2007;356:2505–13.CrossRefGoogle Scholar
  17. 17.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol. 2006;107:1475–8.CrossRefGoogle Scholar
  18. 18.
    Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med. 2007;14(356):2505–13.CrossRefGoogle Scholar
  19. 19.
    Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439–49.CrossRefGoogle Scholar
  20. 20.
    Emery J, Lucassen A, Murphy M. Common hereditary cancers and implications for primary care. Lancet. 2001;7(358):56–63.CrossRefGoogle Scholar
  21. 21.
    King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6.CrossRefGoogle Scholar
  22. 22.
    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossRefGoogle Scholar
  23. 23.
    Fossland VS, Stroop JB, Schwartz RC, Kurtzman SH. Genetic issues in patients with breast cancer. Surg Oncol Clin N Am. 2009;18:53–71.CrossRefGoogle Scholar
  24. 24.
    The American Society of Breast Surgeon Position Statement on BRCA genetic testing for patients with and without breast cancer. 2012. Accessed 26 June 2014.
  25. 25.
    Koibuchi Y, Lino Y, Takei H, Maemura M, Horiguchi J, Yo- Koe T, et al. The effect of mass screening by physical examination combined with regular breast self-examination on clinical stage and course of Japanese women with breast cancer. Oncol Rep. 1998;5:151–5.PubMedGoogle Scholar
  26. 26.
    GIVIO (Interdisciplinary Group for Cancer Care Evaluation). Practice of breast self examination: disease extent at diagnosis and patterns of surgical care. A report from an Italian study. J Epidemiol Community Health. 1991;45:112–6.CrossRefGoogle Scholar
  27. 27.
    Yilmaz MH. Imaging and follow-up after breast reconstruction. J Breast Dis. 2012;1:81–4.Google Scholar
  28. 28.
    Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877.Google Scholar
  29. 29.
    Magnus MC, Ping M, Shen MM, Bourgeois J, Magnus JH. Effectiveness of mammography screening in reducing breast cancer mortality in women aged 39–49 years: a meta-analysis. J Womens Health (Larchmt). 2011;20:845–52.CrossRefGoogle Scholar
  30. 30.
    Kim SJ, Moon WK, Cho N, Chang JM. The detection of recurrent breast cancer in patients with a history of breast cancer surgery: comparison of clinical breast examination, mammography and ultrasonography. Acta Radiol. 2011;52(1):15–20.CrossRefGoogle Scholar
  31. 31.
    Gweon HM, Son EJ, Youk JH, Kim JA, Chung J. Value of the US BI-RADS final assessment following mastectomy: BI-RADS 4 and 5 lesions. Acta Radiol. 2012;53:255–60.CrossRefGoogle Scholar
  32. 32.
    Destounis S, Morgan R, Arieno A, Seifert P, Somerville P, Murphy P. A review of breast imaging following mastectomy with or without reconstruction in an outpatient community center. Breast Cancer. 2011;18:259–67.CrossRefGoogle Scholar
  33. 33.
    Yilmaz MH, Esen G, Ayarcan Y, Aydoğan F, Ozgüroğlu M, Demir G, et al. The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy. Diagn Interv Radiol. 2007;13:13–8.PubMedGoogle Scholar
  34. 34.
    Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, American Society of Clinical Oncology, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5.CrossRefGoogle Scholar
  35. 35.
    Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, European School of Oncology-Metastatic Breast Cancer Task Force, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22:203–10.CrossRefGoogle Scholar
  36. 36.
    Salloum RG, Hornbrook MC, Fishman PA, Ritzwoller DP, O’Keeffe Rossetti MC, et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012;118:5644–51.CrossRefGoogle Scholar
  37. 37.
    Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, American Society of Clinical Oncology, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.CrossRefGoogle Scholar
  38. 38.
    Tolaney SM, Winer EP. Follow-up care of patients with breast cancer. Breast Suppl. 2007;2:S45–50.CrossRefGoogle Scholar
  39. 39.
    Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25:1074–81.CrossRefGoogle Scholar
  40. 40.
    Smith TJ, American Society of Clinical Oncology. The American Society of Clinical Oncology recommended breast cancer surveillance guidelines can be done in a routine office visit. J Clin Oncol. 2005;23:6807.CrossRefGoogle Scholar
  41. 41.
    Elston Lafata J, Simpkins J, Schultz L, Chase GA, Johnson CC, Yood MU, et al. Routine surveillance care after cancer treatment with curative intent. Med Care. 2005;43:592–9.CrossRefGoogle Scholar
  42. 42.
    Coleman SJ, Rubens RD. The clinical course of bone metastasis from breast cancer. Br J Cancer. 1987;55:61–6.CrossRefGoogle Scholar
  43. 43.
    Crippa F, Seregni E, Agresti R, Bombardieri E, Buraggi GL. Bone scintigraphy in breast cancer: a ten years follow up study. J Nucl Biol Med. 1993;37:57–61.PubMedGoogle Scholar
  44. 44.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun. 2012;33:591–6.CrossRefGoogle Scholar
  45. 45.
    Murakami R, Kumita S, Yoshida T, Ishihara K, Kiriyama T, Hakozaki K, et al. FDG-PET/CT in the diagnosis of recurrent breast cancer. Acta Radiol. 2012;53:12–6.CrossRefGoogle Scholar
  46. 46.
    Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712–20.CrossRefGoogle Scholar
  47. 47.
    Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105–12.CrossRefGoogle Scholar
  48. 48.
    Granziera E, Guglieri I, Del Bianco P, Capovilla E, Dona’ B, Ciccarese AA, et al. A multidisciplinary approach to improve preoperative understanding and reduce anxiety: a randomised study. Eur J Anaesthesiol. 2013;30:734–42.CrossRefGoogle Scholar
  49. 49.
    Rajan S, Foreman J, Wallis MG, Caldas C, Britton P. Multidisciplinary decisions in breast cancer: does the patient receive what the team has recommended? Br J Cancer. 2013;108:2442–7.CrossRefGoogle Scholar
  50. 50.
    Taylor C, Shewbridge A, Harris J, Green JS. Benefits of multidisciplinary teamwork in the management of breast cancer. Breast Cancer (Dove Med Press). 2013;5:79–85.Google Scholar
  51. 51.
    Bimes J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.CrossRefGoogle Scholar
  52. 52.
    Perz J, Ussher J, Gilbert E. Loss, uncertainty, or acceptance: subjective experience of changes to fertility after breast cancer. Eur J Cancer Care (Engl). 2014;23:514–22.CrossRefGoogle Scholar
  53. 53.
    Munster PN. Fertility preservation and breast cancer: a complex problem. Oncology (Williston Park). 2013;27:533–9.Google Scholar
  54. 54.
    Sinha G. Pregnancy after breast cancer appears safe. J Natl Cancer Inst. 2012;104:725–6.CrossRefGoogle Scholar
  55. 55.
    Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Breast International Group-North American Breast Cancer Group Endocrine Working Group, et al. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat. 2011;129:309–17.CrossRefGoogle Scholar
  56. 56.
    Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47:74–83.CrossRefGoogle Scholar
  57. 57.
    Kranick JA, Schaefer C, Rowell S, Desai M, Petrek JA, Hiatt RA, et al. Is pregnancy after breast cancer safe? Breast J. 2010;16:404–11.PubMedPubMedCentralGoogle Scholar
  58. 58.
    de Bree E, Makrigiannakis A, Askoxylakis J, Melissas J, Tsiftsis DD. Pregnancy after breast cancer. A comprehensive review. J Surg Oncol. 2010;101:534–42.CrossRefGoogle Scholar
  59. 59.
    Peled R, Carmil D, Siboni-Samocha O, Shoham-Vardi I. Breast cancer, psychological distress and life events among young women. BMC Cancer. 2008;8:245.CrossRefGoogle Scholar
  60. 60.
    Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386–405.CrossRefGoogle Scholar
  61. 61.
    Zainal NZ, Nik-Jaafar NR, Baharudin A, Sabki ZA, Ng CG. Prevalence of depression in breast cancer survivors: a systematic review of observational studies. Asian Pac J Cancer Prev. 2013;14:2649–56.CrossRefGoogle Scholar
  62. 62.
    Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611–35.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Varol Çelik
    • 1
  • Tümay Aydoğan
    • 2
    • 3
  • Mehmet Halit Yilmaz
    • 4
  • Nejdet Fatih Yaşar
    • 5
  • Mahmut Müslümanoğlu
    • 6
  1. 1.Division of Breast Disease, Department of General SurgeryCerrahpasa School of Medicine, Istanbul UniversityIstanbulTurkey
  2. 2.Department of Medical EducationBiruni School of Medicine, Biruni UniversityIstanbulTurkey
  3. 3.Comprehensive Breast Center, Hallmark Health Medical AssociatesStonehamUSA
  4. 4.Department of RadiologyCerrahpasa School of Medicine, Istanbul UniversityIstanbulTurkey
  5. 5.Department of General SurgeryOsmangazi Medical School, Eskişehir Osmangazi UniversityEskişehirTurkey
  6. 6.Department of General Surgery, Surgery DepartmentIstanbul University Medical Faculty, Istanbul Medical SchoolIstanbulTurkey

Personalised recommendations